Skip to content

Comparison of Tegileridine and Sufentanil for Multimodal Analgesia in Gynecological Laparoscopic Surgery: A Randomized Double-blinded Controlled Trial

Comparison of Tegileridine and Sufentanil for Multimodal Analgesia in Gynecological Laparoscopic Surgery: A Randomized Double-blinded Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500112994
Enrollment
Unknown
Registered
2025-11-23
Start date
2025-11-23
Completion date
Unknown
Last updated
2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Interventions

Sufentanil group:General anesthesia was induced with midazolam (2mg), parecoxib sodium (40mg), propofol (1.0-2.5 mg/kg), rocuronium (0.15-0.2 mg/kg) and sufentanil 0.5ug/kg, which were added as needed
Tegiletine group:Tygelidine 0.05mg/kg was given during induction of general anesthesia. No other opioids were used during the procedure. Other anesthesia induction, maintenance and adjuvant drugs were

Sponsors

Obstetrics and Gynecology Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Age: 18 to 75 years old; 2.ASA I–III; 3. Patients who are scheduled to undergo gynecological tumor surgery under combined intravenous-inhalation general anesthesia; 4. Use the analgesic pump after the operation and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1.ASA>= Grade IV; 2.BMI>35 or weight 15 u of morphine equivalent, with a frequency of > 3 days per week or > 1 week within one year); 4. Analgesic drugs have been used within 48 hours before the operation; 5. Long-term history of using non-steroidal anti-inflammatory drugs; 6. Having used drugs that may interfere with the response to analgesic drugs for more than 30 days (such as central alpha-adrenergic drugs, antiepileptic drugs, neuroleptics, antidepressants, antipsychotic drugs); 7. Corticosteroids have been used within 3 months before the operation; 8. Liver and kidney dysfunction; 9. Neurocognitive dysfunction; 10. Heart diseases (including pacemaker implantation and severe bradycardia); 11. History of allergy to anesthetic drugs.

Design outcomes

Primary

MeasureTime frame
Incidence of adverse reactions;The effective number of PCA demands;

Secondary

MeasureTime frame
Pain assessed at rest;Pain assessed at coughing/movement;The worst pain;The first pressing time of the analgesic pump;The total number of PCA demands;

Countries

China

Contacts

Public ContactDu Weijia

Obstetrics and Gynecology Hospital Affiliated to Fudan University

duweijia10317@fckyy.org.cn+86 138 1725 3768

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026